Teclistamab,Daratumumab,Pomalidomide,Lenalidomide,Bortezomib,Nirogacestat
Genmab,Janssen,springworks therapeutics
['majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'nirogacestat', 'majestec-2', 'teclistamab', 'mmsm']
congress #eha2023 | jeffrey matous reports on the majestec-2 phase ib study of teclistamab+ nirogacestat in rrmm. n=28. any ae =100%, grade 3/4 =92.9%. 5 grade 5 teaes. 74% orr, 52% cr across all dose levels. 87.2% responders remained in response at 12 mos #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma